Mor Research Applications, a subsidiary of Clalit Health Services, has
agreed to join in the Aspire
Ventures Precision Medicine Fund and Smart
Health Innovation Lab (iLab). The collaboration is part of a
strategic partnership agreement among Aspire, Penn Medicine Lancaster
General Health (LG Health), Capital BlueCross, Clio Health, Clalit, and
Mor, that benefits all parties in advancing technologies for precision
medicine and achieving international market adoption that improves
healthcare globally.
“Through a robust program of cross-border venture capital with U.S. and
Israel, the U.S. market is being opened to the transformational
technological force of the Start-up Nation. In return, worthy Israeli
start-ups will benefit from unique commitments of U.S. health systems to
provide contracts and reimbursement,” said Essam Abadir, Managing
Partner at Aspire.
Mor Research Applications is the Technology Transfer Office of Clalit
Health Services. Clalit is the largest HMO in Israel and the second
largest in the world, with 4.3 million members, 14 hospitals, and around
2,000 clinics across the country.
Mor provides end-to-end technology transfer services and helps inventors
translate new ideas in the medical fields into beneficial products and
solutions available to health caregivers and patients. Mor’s
commercialization portfolio comprises more than 100 different projects
and companies, from pre-seed to advanced stage, aiming to solve a number
of unmet needs.
The iLab is designed to accelerate the progress of such companies by
finding, fostering, and developing new approaches to healthcare that can
be directly deployed in new markets globally. Established by Aspire, LG
Health, Capital BlueCross, and Clio Health, the iLab connects healthcare
startups with experts across the healthcare field, including investors,
payors, and providers. That access offers startups first-hand knowledge
of the market and how their technology can best serve patients within
that ecosystem.
“The unique international iLab ecosystem we are building has already
proven it can deliver enterprise contracts, reimbursement, and funding
to transformational companies like NeuroFlow, developed by students at
the University of Pennsylvania; Emovi, which came from three
Montreal-based universities; and OneOme, co-founded with scientists of
the Mayo Clinic,” said Kim Ireland, CEO, Smart Health Innovation Lab.
“As the tech transfer office of Clalit, Mor provides direct access to
Israeli health tech innovation we can now expose to the U.S. markets.”
“We’ve been intrigued by the iLab’s market adoption process and its
ability to fast-track technologies into the hands of doctors and
patients,” said Pini Ben-Elazar, Chief Executive Officer at Mor. “This
new partnership not only helps us enter the U.S. market, but represents
a joining of international forces to pursue solutions for the challenges
conceived and developed by Clalit’s professionals. This marks global
growth for all partners via collaboration in an established fund.”
About Aspire Ventures
Aspire
Ventures, an Aspire Universal Company, is a private equity firm
focused on transforming industries and impact investment. Aspire
Ventures leverages its capital, intellectual property and domain
expertise to help bring breakthrough technologies to market faster and
more cost effectively for the benefit of people worldwide.
Aspire Ventures has developed A2I, an adaptive artificial
intelligence platform, to help its portfolio companies offer innovative
technologies in the areas of mobile, cloud, machine learning, and big
data analytics for a variety of industry sectors, most notably
healthcare. Aspire Ventures is leading several initiatives in healthcare
designed to break down silos, foster innovation and integration, and
effect revolutionary change, and the company’s vision for healthcare is
focused on creating a better patient experience through precision
medicine. For more information on Aspire Ventures, please visit https://aspirevc.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190514005724/en/